Resultados de procura - P.V. Plourde

  • Mostrando 1 - 2 Resultados de 2
Limitar resultados
  1. 1
    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression o... por Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany, Ian C. Anderson, Minal Barve, Sibel Blau, Mathew Cherian, Julio A. Peguero, Matthew P. Goetz, P.V. Plourde, David Portman, H.C.F. Moore

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

    Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial por Matthew P. Goetz, N.A. Bagegni, Gerald Batist, Adam Brufsky, Massimo Cristofanilli, Senthil Damodaran, B. Daniel, Gini F. Fleming, William J. Gradishar, Stephanie L. Graff, Maria T. Grosse Perdekamp, Erika Hamilton, Sayeh Lavasani, Alvaro Moreno‐Aspitia, Tracey L. O’Connor, Timothy Pluard, Hope S. Rugo, Sarah Sammons, Lee S. Schwartzberg, Daniel G. Stover, Gregory A. Vidal, G. Wang, Ellen Warner, Rinat Yerushalmi, P.V. Plourde, David Portman, Einav Nili Gal‐Yam

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: